secwatch.observer — SEC 8-K summary
======================================

Issuer:     HAEMONETICS CORP (HAE)
CIK:        0000313143
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0000313143-22-000042
Event type: debt
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 1.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Haemonetics enters amended credit agreement: $280M term loan, $420M revolver, maturity extended to June 2025
--------------------------------------------------------------------------------

- New $420M revolving credit facility (up from $350M) and $280M term loan to replace existing term loan.
- Maturity extended by two years to June 15, 2025; quarterly amortization begins at 2.5% then 5%.
- Interest: Adjusted Term SOFR plus 1.125%–1.750% credit spread based on leverage ratio.
- Financial covenants: max leverage 3.50x (4.00x post-acquisition), min interest coverage 4.00x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313143/000031314322000042/0000313143-22-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313143/000031314322000042/hae-20220726.htm
  HTML page:      https://secwatch.observer/filing/0000313143-22-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer